Novo Nordisk celebrates 75-year commitment to diabetes research

Novo NordiskNovo Nordisk celebrates two milestone anniversaries, which demonstrates the company's long-term commitment to diabetes care and research. The day marks the 75-year anniversary of the Steno Diabetes Center and the 50-year anniversary of the Hagedorn Research Institute.

Both institutions will open their doors to the public on 5 November with a range of exhibitions, film showings, food tastings and presentations available. Visitors can experience 'looking through the body with laser light', learn which role diet and exercise play in diabetes care or hear a talk about the prospects of finding a cure for the disease.

Steno Diabetes Center and Hagedorn Research Institute are responsible for several groundbreaking research results. Among the most notable achievements is the development of protamine insulin – the world's first long-acting insulin, and its successor, Neutral Protamine Hagedorn (NPH) insulin, a more convenient and versatile product which could be successfully mixed with fast-acting insulin. Both were developed at the then Nordisk Insulinlaboratorium and clinically tested at the Steno facility. NPH is still in use as a long-acting insulin.

Today, the research effort at Steno Diabetes Center focuses on the causes of beta cell death as well as on the treatment and prevention of diabetes complications. Research into the prevention and treatment of type 2 diabetes is also a vital area of investigation. In fact, the Steno approach to diet and control has become a role model for diabetes clinics around the world.

Knut Borch-Johnsen, director, professor at Steno Diabetes Center says: "For Steno Diabetes Center, the ultimate goal is cure and prevention, but until this is reached our focus will continue to be optimal care for patients. We develop programmes and treatment strategies which prevent life-threatening complications and improve the quality of life for all patients with diabetes."

Work at the Hagedorn Research Institute deals mainly with how to replace or preserve the insulin-producing beta cell mass, and stem cell research is an important element of this area. The institute works closely with the Research & Development department at Novo Nordisk on the mutual goal of eventually developing a cure for diabetes.

Ole Dragsbæk Madsen, chief of Research at Hagedorn says: "It is a truly unique constellation of a pharmaceutical company to have an independent basic research institution like Hagedorn Research Institute that is devoted to finding a cure for diabetes. The only question is at what point in the future this will happen."

Steno Diabetes Center and Hagedorn Research Institute are open to the public on 5 November between 13.00 and 15.00.

About Novo Nordisk
Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 25,800 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit www.novonordisk.com.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Pfizer receives FDA approval for SUTENT® (sunitini…

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

Efficacy and safety maintained in patients who swi…

Boehringer Ingelheim today announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and reference product Humira...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]